Market capitalization | $492.06m |
Enterprise Value | $289.37m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | -227.85 |
P/B ratio (TTM) P/B ratio | 2.44 |
Revenue growth (TTM) Revenue growth | -100.32% |
Revenue (TTM) Revenue | $-1.27m |
EBIT (operating result TTM) EBIT | $-171.35m |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
6 Analysts have issued a Amylyx Pharmaceuticals forecast:
6 Analysts have issued a Amylyx Pharmaceuticals forecast:
Mar '25 |
+/-
%
|
||
Revenue | -1.27 -1.27 |
100%
100%
|
|
Gross Profit | -10 -10 |
104%
104%
|
|
EBITDA | -171 -171 |
113%
113%
|
EBIT (Operating Income) EBIT | -171 -171 |
111%
111%
|
Net Profit | -219 -219 |
208%
208%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in the provision of disease-modifying solutions for neurodegenerative diseases. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Josh Klee |
Employees | 123 |
Founded | 2013 |
Website | www.amylyx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.